Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins

Journal of Clinical Investigation

Volumn 118, Issue 9, 2008, Pages 3109-3122

  Ziegler, David S ^a,e   Wright, Renee D ^a   Kesari, Santosh ^b,c   Lemieux, Madeleine E ^a   Tran, Mary A ^d   Jain, Monish ^d   Zawel, Leigh ^d   Kung, Andrew L ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CASPASE; ETOPOSIDE; IMATINIB; INHIBITOR OF APOPTOSIS PROTEIN; LBW 242; NILOTINIB; NVP AEW 541; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRICIRIBINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PERMEABILIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, BIOLOGICAL; NEURONS; OLIGOPEPTIDES; PIPERAZINES; PYRIMIDINES;

EID: 51349124367     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34120     Document Type: Article

References (62)

1. DeAngelis, L.M. 2001. Brain tumors. N. Engl. J. Med. 344:114-123.
2. Kitange, G.J., Templeton, K.L., and Jenkins, R.B. 2003. Recent advances in the molecular genetics of primary gliomas. Curr. Opin. Oncol. 15:197-203.
3. Broniscer, A., and Gajjar, A. 2004. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 9:197-206.
4. Mellinghoff, I.K., et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353:2012-2024.
5. Gammeltoft, S., Ballotti, R., Kowalski, A., Westermark, B., and Van Obberghen, E. 1988. Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res. 48:1233-1237.
6. Kiaris, H., Schally, A.V., and Varga, J.L. 2000. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia. 2:242-250.
7. Fleming, T.P., et al. 1992. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52:4550-4553.
8. Hermanson, M., et al. 1992. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52:3213-3219.
9. Guha, A., Dashner, K., Black, P.M., Wagner, J.A., and Stiles, C.D. 1995. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer. 60:168-173.
10. Kilic, T., et al. 2000. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60:5143-5150.
11. Wen, P.Y., et al. 2006. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 12:4899-4907.
12. Rich, J.N., et al. 2004. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22:133-142.
13. Reardon, D.A., Rich, J.N., Friedman, H.S., and Bigner, D.D. 2006. Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol. 24:1253-1265.
14. Camp, E.R., et al. 2005. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11:397-405.
15. Chakravarti, A., Chakladar, A., Delaney, M.A., Latham, D.E., and Loeffler, J.S. 2002. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 62:4307-4315.
16. Servidei, T., Riccardi, A., Sanguinetti, M., Dominici, C., and Riccardi, R. 2006. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation. J. Cell. Physiol. 208:220-228.
17. Lefranc, F., Brotchi, J., and Kiss, R. 2005. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol. 23:2411-2422.
18. Ziegler, D.S., Kung, A.L., and Kieran, M.W. 2008. Anti-apoptosis mechanisms in malignant gliomas. J. Clin. Oncol. 26:493-500.
19. Nakada, M., et al. 2007. Molecular targets of glioma invasion. Cell. Mol. Life Sci. 64:458-478.
20. Bogler, O., and Mikkelsen, T. 2005. Angiogenesis and apoptosis in glioma: two arenas for promising new therapies. J. Cell. Biochem. 96:16-24.
21. Ishii, N., et al. 1999. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9:469-479.
22. Steinbach, J.P., and Weller, M. 2004. Apoptosis in gliomas: molecular mechanisms and therapeutic implications. J. Neurooncol. 70:247-256.
23. Wagenknecht, B., et al. 1999. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 6:370-376.
24. Chen, Z., et al. 1999. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem. Biophys. Res. Commun. 264:847-854.
25. Chakravarti, A., et al. 2002. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20:1063-1068.
26. Fulda, S., Wick, W., Weller, M., and Debatin, K.M. 2002. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8:808-815.
27. Li, L., et al. 2004. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 305:1471-1474.
28. Roa, W.H., et al. 2003. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin. Invest. Med. 26:231-242.
29. Fesik, S.W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer. 5:876-885.
30. Chauhan, D., et al. 2007. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 109:1220-1227.
31. Giagkousiklidis, S., et al. 2005. Sensitization for gamma-irradiation- induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 65:10502-10513.
32. Mizukawa, K., et al. 2006. Synthetic Smac peptide enhances the effect of etoposide-induced apoptosis in human glioblastoma cell lines. J. Neurooncol. 77:247-255.
33. Arnt, C.R., Chiorean, M.V., Heldebrant, M.P., Gores, G.J., and Kaufmann, S.H. 2002. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277:44236-44243.
34. Groothuis, D.R. 2000. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro. Oncol. 2:45-59.
35. Shamah, S.M., Stiles, C.D., and Guha, A. 1993. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol. Cell. Biol. 13:7203-7212.
36. Klein, S., McCormick, F., and Levitzki, A. 2005. Killing time for cancer cells. Nat. Rev. Cancer. 5:573-580.
37. Weisberg, E., et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 7:129-141.
38. Gaither, A., et al. 2007. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 67:11493-11498.
39. Vince, J.E., et al. 2007. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 131:682-693.
40. Varfolomeev, E., et al. 2007. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 131:669-681.
41. Garcia-Echeverria, C., et al. 2004. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 5:231-239.
42. Bruns, C.J., et al. 2000. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60:2926-2935.
43. Alikhani, M., Alikhani, Z., and Graves, D.T. 2005. FOXO1 functions as a master switch that regulates gene expression necessary for tumor necrosis factor-induced fibroblast apoptosis. J. Biol. Chem. 280:12096- 12102.
44. Koseki, T., Inohara, N., Chen, S., and Nunez, G. 1998. ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. U. S. A. 95:5156-5160.
45. Hong, Y.M., et al. 2003. Down-regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia. FEBS Lett. 543:170-173.
46. Phillips, H.S., et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 9:157-173.
47. Sun, L., et al. 2006. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 9:287-300.
48. Rubin, J.B., et al. 2003. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. U. S. A. 100:13513-13518.
49. Szentirmai, O., et al. 2006. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery. 58:365-372.
50. Kung, A.L. 2007. Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96:191-212.
51. Singh, S.K., et al. 2004. Identification of human brain tumour initiating cells. Nature. 432:396-401.
52. Haas-Kogan, D.A., et al. 2005. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97:880-887.
53. Gustafsson, A.B., Tsai, J.G., Logue, S.E., Crow, M.T., and Gottlieb, R.A. 2004. Apoptosis repressor with caspase recruitment domain protects against cell death by interfering with Bax activation. J. Biol. Chem. 279:21233-21238.
54. Wang, M., Qanungo, S., Crow, M.T., Watanabe, M., and Nieminen, A.L. 2005. Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei. FEBS Lett. 579:2411-2415.
55. Mercier, I., et al. 2005. ARC, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo- and radiation-resistance. Cell Death Differ. 12:682-686.
56. Matei, D., Chang, D.D., and Jeng, M.H. 2004. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin. Cancer Res. 10:681-690.
57. Coleman, R.L., et al. 2006. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol. Oncol. 101:126-131.
58. Krystal, G.W., Honsawek, S., Litz, J., and Buchdunger, E. 2000. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:3319-3326.
59. Hoff, P.M., and Ellis, L.M. 2007. Targeted therapy trials: approval strategies, target validation, or helping patients? J. Clin. Oncol. 25:1639-1641.
60. Wright, C.W., and Duckett, C.S. 2005. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115:2673-2678.
61. Deveraux, Q.L., Welsh, K., and Reed, J.C. 2000. Purification and use of recombinant inhibitor of apoptosis proteins as caspase inhibitors. Methods Enzymol. 322:154-161.
62. Ligon, K.L., et al. 2007. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 53:503-517.